Stockreport

Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis [Financial Post (Toronto, Ontario, Canada)]

GENFIT S.A. - American Depositary Shares  (GNFT) 
PDF (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Appro [Read more]